InvestorsHub Logo
Followers 196
Posts 678
Boards Moderated 0
Alias Born 10/27/2016

Re: None

Monday, 03/05/2018 2:27:58 PM

Monday, March 05, 2018 2:27:58 PM

Post# of 346
Yes, you're correct. About 25 m shares o/s.

Given the phase 3 celiac drug candidate, valuation of $250m - $750 m seems about right in my view. I've known this company for 1.5 years. Invested when it was a private company and have meaningful exposure currently. The technology is valuable and it wouldn't surprise me if they also get, at some point, strategic interest.